The persistence of latent HIV within T cells, which is maintained in part by the activity of histone deacetylases (HDACs), means that it is difficult to eradicate HIV infection. Archin et al. investigated the effects of the HDAC inhibitor vorinostat in patients with HIV who were receiving antiretroviral therapy. Following initial safety and tolerability dosing, each of eight patients given a single dose of vorinostat had increased HIV RNA expression (a proximal measure of reduced latent infection) in resting T cells. This suggests that HDAC inhibitors — which are already approved for cancer indications — could be used clinically to awaken latent HIV.
ORIGINAL RESEARCH PAPER
Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012)
Rights and permissions
About this article
Cite this article
Harrison, C. Waking up latent HIV. Nat Rev Drug Discov 11, 674 (2012). https://doi.org/10.1038/nrd3833
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3833